Trials / Conditions / Blastic Plasmacytoid Dendritic Cell Neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm

20 registered clinical trials studyying Blastic Plasmacytoid Dendritic Cell Neoplasm — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hig NCT06013423	Fred Hutchinson Cancer Center	Phase 2
Recruiting	A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies NCT05362773	MacroGenics	Phase 1
Recruiting	Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm NCT04216524	M.D. Anderson Cancer Center	Phase 2
Terminated	Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant NCT04317781	M.D. Anderson Cancer Center	Phase 2
Recruiting	Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Bloo NCT03779854	Fred Hutchinson Cancer Center	Phase 2
Completed	Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. NCT03974971	Samsung Medical Center	—
Completed	Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) NCT03485547	Dana-Farber Cancer Institute	Phase 1
Terminated	Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN NCT03386513	AbbVie	Phase 1 / Phase 2
Terminated	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906	Fred Hutchinson Cancer Center	Phase 2
Recruiting	SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk My NCT03113643	Dana-Farber Cancer Institute	Phase 1
Terminated	Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma NCT03075553	Mayo Clinic	Phase 2
Completed	PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Mali NCT02730312	Xencor, Inc.	Phase 1
Completed	Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma NCT02652715	Mayo Clinic	N/A
Active Not Recruiting	Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT02159495	City of Hope Medical Center	Phase 1
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985	Fred Hutchinson Cancer Center	Phase 2
Completed	Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) NCT02859623	Centre Hospitalier Universitaire de Besancon	—
Completed	DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes NCT00397579	University of Texas Southwestern Medical Center	Phase 1 / Phase 2
Completed	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919	National Cancer Institute (NCI)	Phase 1
Completed	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235	Fred Hutchinson Cancer Center	N/A